# Vienna Challenge Chamber Study Using RV658 in Subjects With Allergic Rhinitis

> **NCT01230619** · PHASE2 · COMPLETED · sponsor: **Respivert Ltd** · enrollment: 75 (actual)

## Conditions studied

- Seasonal Allergic Rhinitis

## Interventions

- **DRUG:** RV568
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01230619
- **Lead sponsor:** Respivert Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2010-11
- **Final completion:** 2010-12
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2010-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01230619

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01230619, "Vienna Challenge Chamber Study Using RV658 in Subjects With Allergic Rhinitis". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01230619. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*